Roche sends a warning to Illumina shareholders; Replagal users demand answers on Shire NDA;

@FierceBiotech: AstraZeneca scouts new drug deals to silence a chorus of critics. Story | Follow @FierceBiotech

@JohnCFierce: Burrill counted up all the early-stage venture funds coming together and ID'd $2.6B over just a few weeks. Serious $$. Release | Follow @JohnCFierce

@RyanMFierce: In case you missed, device that can detect neural activity called iBrain in the spotlight, famous ALS patient outfitted: Article | Follow @RyanMFierce

> In a push for shareholder support for its $6.7 billion offer for Illumina ($ILMN), Roche ($RHHBY) warned investors that they could take what's on the table or settle for much less if the pharma giant decides to drop the bid. Story

> Bloomberg today covers the curious case of Replagal as patients ask why the NDA was unexpectedly pulled by Shire ($SHPGY). Story

> The Muscular Dystrophy Association awarded $120,000 to Cambridge, MA-based Catabasis Pharmaceuticals to support work on CAT-1004 and CAT-1040 for Duchenne muscular dystrophy. Release

> Connecticut Innovations, a quasi-public group, has invested $269,160 in BioRelix, which is developing antibiotics. Story

Pharma News

@FiercePharma: One big hit to script numbers: Seniors avoiding the doc, holding off on refills for cost reasons--Bloomberg. More | Follow @FiercePharma

> U.S. drug spending up, thanks to new drug launches. More

> Pfizer eyes ad agency work for cost-cutting. Item

Medical Devices News

@FierceMedDev: St Jude To Stop Selling Another Version Of Defibrillator Wires | Fox Business. News | Follow @FierceMedDev

> Study: Metal hips don't heighten cancer risks. Item

> Imaging boosts breast cancer finds. Story

Biomarkers News

> DNA biomarker pinpoints hep B liver cancers. More

> Survivin could be key to survival in pancreatic cancer. Story

> Looking closely: Inflammation imaging as a depression biomarker. Piece

> Allergy biomarkers could track treatment response. Article

> Biomarkers could tag breast cancer recurrence earlier. Item

Drug Delivery News

> AZ spinoff licenses novel constipation drug to Japanese firm. News

> Novartis touts positive results for COPD inhalant. Story

> After Astellas fallout, Zogenix strikes deal with Battelle to market DosePro. Article

> Is ImmunoGen overvalued? Item

> INSYS and Aptar launch under-the-tongue delivery for cancer pain drug. More

And Finally... Investigators at Oxford found that increasing height and increased body mass index among women who have never taken menopausal hormone therapy are risk factors for developing ovarian cancer. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.